ExodusPoint Capital Management’s Astria Therapeutics ATXS Stock Holding History

ExodusPoint Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-48,636	Closed	-$637K	–	1548
2025 Q4	$637K	Buy	48,636 +12,009	+33%	+$143K	0.01%	1126
2025 Q3	$267K	Sell	36,627 -42,413	-54%	-$287K	﹤0.01%	1331
2025 Q2	$424K	Buy	79,040 +42,134	+114%	+$204K	﹤0.01%	1185
2025 Q1	$197K	Buy	+36,906	New	+$258K	﹤0.01%	1300
2021 Q1	–	Sell	-1,998	Closed	-$26K	–	2111
2020 Q4	$26K	Buy	+1,998	New	+$35.6K	﹤0.01%	1891

ExodusPoint Capital Management's ATXS Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 48,636 shares — an estimated $637K sold.

ExodusPoint Capital Management first reported a position in ATXS in Q4 2020 and held it in 5 quarters. The position peaked at $637K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

ExodusPoint Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 48,636 Astria Therapeutics shares in Q1 2026, an estimated $637K.
ExodusPoint Capital Management first reported a position in Astria Therapeutics in Q4 2020 and held it in 5 quarters.
ExodusPoint Capital Management's Astria Therapeutics position peaked at $637K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.